Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6

Benzinga · 05/08 11:14
Chardan Capital analyst Keay Nakae downgrades Seres Therapeutics (NASDAQ:MCRB) from Buy to Neutral and raises the price target from $1.25 to $6.